ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
about
A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment toolBeyond BRAF: where next for melanoma therapy?Investigation of cAMP microdomains as a path to novel cancer diagnosticsPhosphodiesterase-8A binds to and regulates Raf-1 kinaseMTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB167-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling.MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.Molecular targeted therapies in metastatic melanoma.MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.Local cAMP signaling in disease at a glancePhospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.Acrodysostosis syndromes.A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.The role of mitogen- and stress-activated protein kinase pathways in melanoma.Signal control through Raf: in sickness and in health.MAP kinase signaling and inhibition in melanoma.MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentationMicrophthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.Melanoma-associated GRM3 variants dysregulate melanosome trafficking and cAMP signaling.Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.PARKIN Inactivation Links Parkinson's Disease to Melanoma.Ras oncoprotein disrupts the TSH/CREB signaling upstream adenylyl cyclase in human thyroid cell.Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells.Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.RAF-isotype switching: from B to C through PDE.Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis.Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram.
P2860
Q26773564-84691DC1-B61A-4B87-9835-45B1AFE59805Q27006853-02EB2FBA-8056-4040-AA04-210AA7F18714Q27023080-12BE467F-5800-4204-ACF8-45F46185ED0FQ28118406-49224C07-A6D0-4AF0-BF4C-B02E883BA479Q28576369-70190BE8-7473-4C83-BC83-43E3661C9A19Q34552639-81552BBF-E087-4A53-AC13-AD4D4F7CD0E7Q34572036-A84DE717-1B86-4581-86A4-3D8636AA44D8Q34622439-743DB32D-A76C-40F8-8B5B-2B45E5A86625Q35182739-36025056-D32E-4E0E-B2DF-3D2BD4BEFD82Q35262625-2452ADEC-184F-45C9-906A-6798BF655A08Q35377816-182F680D-8DD7-4DC2-BFD1-A7F43C99D586Q35693850-961878B8-C1D1-4B61-A594-66C0C0976CDFQ36209203-0CB60566-18D0-42B4-AB6D-A53091EE75F2Q36682132-90E797B8-6473-498E-9122-A7C7D3E5BA28Q36931453-D302516C-8CD3-4F29-8BD2-69094AEC9B27Q36984179-2E35404B-7187-4FAE-AB24-23A0FB7FC9FBQ37117708-7A9E738E-3386-405B-878E-002109E1B09FQ37189612-C57BD7B0-9471-4600-87A2-FAEB29AE6B49Q37226387-79A1F58D-C621-4FD7-AF2D-766F07A7B9DFQ37295744-87CB89DB-C9EC-4C2D-8370-B183690A8390Q37394504-1D7C8EA6-9BA9-4875-9FFA-07575B15A329Q37405329-26A08C20-5DBB-49A2-B02D-EDB0D12D0A17Q37510558-A14D3A6F-B622-42D3-A531-7722A3D95B02Q37689575-160E3010-D827-4FB1-9C1A-3A4BBD15FC37Q37931402-9A51074D-EB69-4192-8000-2B66EB6EB43CQ37965017-C5F46788-F3C7-4001-907C-432E04DB4E31Q38040353-763E7C8D-CE82-4519-A5FA-A3815D82C47FQ38210121-3EACB8F4-B7AB-41A8-A8CE-7B977BFC3B1FQ38394400-3CDC3A1E-DC4C-4B66-BCFD-544C870D4B5FQ38710970-53034373-133D-4F40-8912-B774C04C961FQ38782682-D93682DA-DAB6-45DA-A852-3029BB4322CEQ38786647-0BC5AB33-B0DE-4F9B-AC9F-E454EB324D75Q38810658-58274B4A-2D1C-4E27-82ED-60FBA2311623Q38995868-D9CC2913-159C-4916-8129-365E0D9EB8DDQ39308493-9612F245-C35A-49F0-8C10-5722196A3E0FQ42324596-D9447F2F-55FF-49A1-AC2E-8096D5577FDCQ42516625-BA36C823-5425-45A7-9A6A-733C4E691D90Q43103116-F8E4F78F-53A8-472A-B868-750EEA5A4837Q44980700-649CBF87-6ADD-4D42-86E1-C40C86A257B1Q48226824-0E2AD0A3-6AC2-43AB-96C0-FD06B110B877
P2860
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@en
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@nl
type
label
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@en
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@nl
prefLabel
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@en
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@nl
P2093
P356
P1476
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
@en
P2093
Amélie Marquette
Armand Bensussan
Jocelyne André
Martine Bagot
Nicolas Dumaz
P2888
P304
P356
10.1038/NSMB.2022
P577
2011-04-10T00:00:00Z
P5875
P6179
1036046219